ArticleBiomarker insights2007
Proteomics and mass spectrometry for cancer biomarker discovery.
Article in Biomarker insights, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Blood Plasma Analysis in Ovarian Cancer Patients Using an AFM/MS Approach: Effect of Sample Dilution on Proteome Depth.International journal of molecular sciences · 2026Article
- Implementation of MALDI Mass Spectrometry Imaging in Cancer Proteomics Research: Applications and Challenges.Journal of personalized medicine · 2020Review
- Article
- Improved signal processing and normalization for biomarker protein detection in broad-mass-range TOF mass spectra from clinical samples.Proteomics. Clinical applications · 2011Article
- Enhanced sensitivity for selected reaction monitoring mass spectrometry-based targeted proteomics using a dual stage electrodynamic ion funnel interface.Molecular & cellular proteomics : MCP · 2011Article
- Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer.Clinical proteomics · 2010Article
- Proteomic strategies and challenges in tumor metastasis research.Clinical & experimental metastasis · 2010Review
- Fast proteomic protocol for biomarker fingerprinting in cancerous cells.Journal of chromatography. A · 2010Article
- Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT).Journal of proteome research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteomics is a rapidly advancing field not only in the field of biology but also in translational cancer research. In recent years, mass spectrometry and associated technologies have been explored to identify proteins or a set of proteins specific to a given disease, for the purpose of disease detection and diagnosis. Such biomarkers are being investigated in samples including cells, tissues, serum/plasma, and other types of body fluids. When sufficiently refined, proteomic technologies may pave the way for early detection of cancer or individualized therapy for cancer. Mass spectrometry approaches coupled with bioinformatic tools are being developed for biomarker discovery and validation. Understanding basic concepts and application of such technology by investigators in the field may accelerate the clinical application of protein biomarkers in disease management.
Indexed as
Identifiers
19662217PMC2717808What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.